Related Experiment Video
Updated: Aug 20, 2026
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis
Banu Anlar1, Omer Faruk Aydin, Alev Guven
1Hacettepe University, Department of Pediatric Neurology, Ankara, Turkey. banlar@hacettepe.edu.tr
Background:
Few effective treatment methods are available for subacute sclerosing panencephalitis (SSPE),an infection associated with the measles virus. Interferons have shown some benefit in previous studies and clinical practice.
Objective:
The purpose of this study was to compare the efficacy of 2 different regimens of interferon-beta(IFN-beta) in the treatment of SSPE in pediatric patients.
Methods:
We retrospectively compared the results obtained with 2 regimens of IFN-beta1a: 60 microg administered intramuscularly once weekly (IFN-beta 1/wk), or 22 microg administered subcutaneously 3 times per week (IFN-beta 3/wk). All patients also received oral inosiplex 50 to 100 mg/kg daily, a treatment known to have partial efficacy in SSPE. Patients who continued treatment for at least 3 months and had at least 1 year of follow-up data were evaluated. Clinical parameters included the Neurological Disability Index (NDI), a measurement of mental, motor, and sensory functions; disease stage; and mental status. Data obtained at 6 and 12 months were compared with those at the time of diagnosis, and the percent change from baseline was calculated. A satisfactory clinical response was defined as reduction or stabilization of the NDI or stage improvement at 6 or 12 months.
Results:
Patients treated with IFN-beta 3/wk had increased survival time (P < 0.02) and higher clinical response rates compared with those treated with IFN-beta 1/wk (P < 0.05). When stage 2 and stage 3 patients were evaluated separately, survival was significantly longer (P = 0.007) and the rate of progression slower in both stage groups with IFN-beta 3/wk.
Conclusion:
The results obtained for this patient sample suggest that IFN-beta administered subcutaneously times per week combined with inosiplex may be an effective treatment option in SSPE. This treatment regimen warrants further study.
Insights
Subacute sclerosing panencephalitis (SSPE) treatment improved with subcutaneous interferon-beta (IFN-beta) 3 times weekly plus inosiplex. This regimen showed increased survival and better clinical response rates in pediatric patients compared to weekly intramuscular IFN-beta.
Area of Science:
- Neurology
- Virology
- Immunology
Background:
- Subacute sclerosing panencephalitis (SSPE) is a rare, progressive neurological disease associated with measles virus infection.
- Effective treatments for SSPE are limited, necessitating research into novel therapeutic strategies.
- Interferon-beta (IFN-beta) has demonstrated potential benefits in previous SSPE studies and clinical practice.
Purpose of the Study:
- To compare the efficacy of two distinct interferon-beta-1a (IFN-beta) regimens in treating pediatric patients with SSPE.
- To evaluate the impact of different IFN-beta administration schedules on clinical outcomes in SSPE.
Main Methods:
- Retrospective comparison of two IFN-beta-1a treatment protocols: 60 mcg intramuscularly weekly (IFN-beta 1/wk) versus 22 mcg subcutaneously three times weekly (IFN-beta 3/wk).
- All patients received daily oral inosiplex (50-100 mg/kg).
- Evaluation included patients with at least 3 months of treatment and 1 year of follow-up, assessing the Neurological Disability Index (NDI), disease stage, and mental status.
Main Results:
- The IFN-beta 3/wk regimen resulted in significantly increased survival time (P < 0.02) and higher clinical response rates (P < 0.05) compared to IFN-beta 1/wk.
- In stage 2 and stage 3 SSPE patients, the IFN-beta 3/wk group exhibited significantly longer survival (P = 0.007) and a slower rate of disease progression.
- Satisfactory clinical response was defined as NDI reduction/stabilization or stage improvement at 6 or 12 months.
Conclusions:
- Subcutaneous administration of IFN-beta three times per week, in combination with inosiplex, appears to be an effective treatment for SSPE.
- This specific treatment regimen warrants further investigation in larger, prospective studies.
- The findings suggest a promising therapeutic option for improving outcomes in pediatric SSPE patients.